Management of arrhythmias in heart failure

Congestive Heart Failure

Volumn 9, Issue 2, 2003, Pages 91-99

  Ellison, Kristin E ^b   Stevenson, William G ^a   Sweeney, Michael O ^b   Epstein, Laurence M ^b   Maisel, William H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TOCAINIDE;

ANTICOAGULATION; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOXICITY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INOTROPISM; LONG QT SYNDROME; LUNG TOXICITY; META ANALYSIS; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; REVIEW; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; SURVIVAL TIME; SYNCOPE; TORSADE DES POINTES;

EID: 0345269124     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2003.00271.x     Document Type: Review

References (77)

1. Cohn JN, Johnson GR, Shabetai R, et al., for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87:V15-V16.
2. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comments]. Lancet. 1999;353:2001-2007.
3. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial [see comments]. Lancet. 1999;353:9-13.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
5. Nagele H, Rodiger W. Sudden death and tailored medical therapy in elective candidates for heart transplantation. J Heart Lung Transplant. 1999;18:869-876.
6. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol. 1997;30:1589-1597.
7. Cohn JN, Goldstein SO, Greenberg BH, et al., for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure [see comments]. N Engl J Med. 1998;339:1810-1816.
8. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842-850.
9. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611-616.
10. Stevenson WG, Sweeney MO. Arrhythmias and sudden death in heart failure. Jpn Circ J. 1997;61:727-740.
11. Buxton AE, Lee KL, Fisher JD, et al., for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease [see comments] [published erratum appears in N Engl J Med. 2000;342(17):1300]. N Engl J Med. 1999;341:1882-1890.
12. Moss AJ, Hall XJ, Cannom DS, et al., for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia [see comments]. N Engl J Med. 1996;335:1933-1940.
13. Stevenson WG, Stevenson LW, Weiss J, et al. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. Am Heart J. 1988;116:1447-1454.
14. Turitto G, Ahuja RK, Caref EB, et al. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. J Am Coll Cardiol. 1994;24:1523-1528.
15. Teerlink JR, Jalaluddin M, Anderson S, et al., for the PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. Circulation. 2000;101:40-46.
16. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993;88:2953-2961.
17. Tomaselli GF, Rose J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol. 2000;15:202-208.
18. De Mello WC. Cell coupling and impulse propagation in the failing heart [see comments]. J Cardiovasc Electrophysiol. 1999;10: 1409-1420.
19. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.
20. Grubman EM, Pavri BB, Shipman T, et al. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol. 1998;32: 1056-1062.
21. Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation [see comments]. Circulation. 1995;92:3273-3281.
22. Flaker GC, Blackshear JL, McBride R, et al., for the Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20:527-532.
23. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure [published erratum appears in J Am Coll Cardiol. 1997; 30(7):1902]. J Am Coll Cardiol. 1996;28:1458-1463.
24. Nul DR, Doval HC, Grancelli HO, et al., for the GESICA-GEMA Investigators (Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina). Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 1997;29:1199-1205.
25. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure [see comments]. N Engl J Med. 1995;333:77-82.
26. Massie BM, Shah NB, Pitt B, et al. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. Am Heart J. 1996;132:130-136.
27. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials [see comments]. Lancet. 1997;350:1417-1424.
28. Massie BM, Fisher SG, Radford M, et al., for the CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure [published erratum appears in Circulation. 1996;94(10):2668]. Circulation. 1996;93:2128-2134.
29. Gottlieb SS, Riggio DW, Lauria S, et al. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994;23: 560-564.
30. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al., for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction [see comments]. N Engl J Med. 1999;341:857-865.
31. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol. 1998;81:869-876.
32. Roy D, Talajic M, Dorian P, et al., for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-20.
33. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias [see comments]. N Engl J Med. 1997;337: 1576-1583.
34. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101:1297-1302.
35. Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study [see comments]. Circulation. 2000;101:1660-1664.
36. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
37. Rosenqvist M, Beyer T, Block M, et al., for the European 7219 Jewel ICD Investigators. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study [published erratum appears in Circulation. 1998;98(23): 2647]. Circulation. 1998;98:663-670.
38. Connolly SJ, Kerr CR, Gent M, et al., for the Canadian Trial of Physiologic Pacing Investigators. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med. 2000;342:1385-1391.
39. Sutandar A, Solimon S, Kaddaha R, et al. Should all patients receive a dual chamber device? Unanticipated use of the implantable defibrillator as a pacemaker. J Am Coll Cardiol. 2000; 35:127A.
40. Auricchio A, Stellbrink C, Block M, et al., for the Pacing Therapies for Congestive Heart Failure Study Group and the Guidant Congestive Heart Failure Research Group. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation. 1999;99: 2993-3001.
41. Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol. 1998;32:1825-1831.
42. Nielsen JC, Bottcher M, Nielsen TT, et al. Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing-effect of pacing mode and rate. J Am Coll Cardiol. 2000;35:1453-1461.
43. Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation. 1999; 99:1567-1573.
44. Leclercq C, Victor F, Alonso C, et al. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic atrial fibrillation. Am J Cardiol. 2000;85:1154-1156, A9.
45. Daubert JC, Linde C, Cazeau S, et al. Clinical effects of biventricular pacing in patients with severe heart failure and normal sinus rhythm: results from the Multisite Stimulation in Cardiomyopathy-MUSTIC-Group I. Circulation 2000;102:694A.
46. Walker S, Levy TM, Paul VE. Biventricular pacing decreased ventricular arrhytmia. Circulation. 2000;102:692A.
47. Higgins SL, Yong P, Scheck D, et al. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. J Am Coll Cardiol. 2000;36:824-827.
48. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. Circulation. 1997;96:3273-3277.
49. Bocker D, Bansch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation. 1998;98:1636-1643.
50. Domanski MJ, Sakseena S, Epstein AE, et al., for the AVID Investigators (Antiarrhythmics Versus Implantable Defibrillators). Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias [see comments]. J Am Coll Cardiol. 1999;34:1090-1095.
51. Mecca A, Barakat T, Guo H, et al. Implantable cardioverter defibrillator therapy for patients with life-threatening ventricular arrhythmias and severe heart failure. Am J Cardiol. 2000;86: 875-877.
52. Saxon LA, Wiener I, DeLurgio DB, et al. Implantable defibrillators for high-risk patients with heart failure who are awaiting cardiac transplantation. Am Heart J 1995;130:501-506.
53. Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up [see comments].J Am Coll Cardiol. 1991;18:1711-1719.
54. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients [see comments]. J Cardiovasc Electrophysiol. 1993;4:253-262.
55. Stevenson WG, Middlekauff HR, Stevenson LW, et al. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment of advanced heart failure. Am Heart J. 1992;124:123-130.
56. Anderson JL, Hallstrom AP, Epstein AE, et al. for the AVID Investigators. Design and results of the Antiarrhythmics vs. Implantable Defibrillators (AVID) registry. Circulation. 1999;99: 1692-1699.
57. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol. 2000;85:981-985.
58. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator [see commentsl. J Am Coll Cardiol. 1999;33:1964-1970.
59. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cordiol. 1993;21:110-116.
60. Singh SN, Fisher SG, Carson PE, et al., for the Department of Veterans Affairs CHF STAT Investigators. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol. 1998;32:942-947.
61. Doval HC, Nul DR, Grancelli HO, et al., for the GESICA-GEMA Investigators nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death [see comments]. Circulation. 1996;94:3198-203.
62. Buxton AE, Lee KL, DiCarlo L, et al., for the Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med. 2000;342:1937-1945.
63. Klein H, Auricchio A, Reek S, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol. 1999;83: 91D-97D.
64. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703.
65. Deedwania PC, Singh BN, Ellenbogen K, et al., for the Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation. 1998;98:2574-2579.
66. Carson PE, Johnson GR, Dunkman WB, et al., for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. Circulation. 1993;87:VI102-110.
67. Dries DL, Domanski MJ, Waclawiw MA, et al. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79: 909-913.
68. Khand AU, Rankin AC, Kaye GC, et al. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614-632.
69. Tuinenburg AE, Van Gelder IC, Van Den Berg MP, et al. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart. 1999;82:486-493.
70. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715.
71. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study [see comments]. Circulation. 1998;98:953-960.
72. Kay GN, Ellenbogen KA, Giudici M, et al., for the APT Investigators. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation [see comments]. J Intervent Card Electrophysiol. 1998;2:121-135.
73. Vanderheyden M, Goethals M, Anguera I, et al. Hemodynamic deterioration following radiofrequency ablation of the atrioventricular conduction system. Pacing Clin Electrophysiol. 1997;20: 2422-2428.
74. Geelen P, Brugada J, Andries E, et al. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol. 1997;20:343-348.
75. Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898-1904.
76. Paydak H, Kall JG, Burke MC, et al. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: time to onset, determinants, and clinical course. Circulatian. 1998;98:315-322.
77. Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation [see comments]. J Cardiovcasc Electrophysiol. 1998;9:462-469